Jim Foster: So, yes; we like our footprint in several ways. We like the geographic footprint we have, and we like the types of services we do with the specific businesses and so, that seems to be working well in terms of supporting clients, some of whom are interested in proximity. We certainly have enough capacity to take on additional large strategic deals, should that happen. I think on our last call we commented that, we could do two or three of those with our current footprint, and then we would simply have to open some buildings that were constructed, but never open. And we also have some space that was constructed, but never caged. So we have a good amount of space for the foreseeable future certainly three plus years I’d say. A capacity utilization, well we don’t give the number, improved during 2011 its not, it didn’t improve to the level that we would like it to be as for optimal margin contribution, but all the work that we’re doing sort of a stable, regulated tox activity, but also increasing amounts of non-GLP Discovery work should continue to fill up the space, sort of systematically that will obviously improve the margins as that happens. So we should have sufficient space to take on the type of work that we’re talking to clients about now.Robbie Fatta – William Blair & Company: Great. Thanks very much.
Jim Foster: Not really Eric, its been pretty consistent through probably the last couple of years, it seems to have leveled off, that’s probably a commentary on the overall amount of work that’s being done throughout the system since we do supply our animals to many of our competitors as well, I think we have a pretty good view of that. The good news is it’s leveled off and we continue to get price increases on top of those. Conversely sales in the inbred strains and immunocompromised strains have been relatively strong, so from a value proposition point of view those tend to offset one and other reasonably well.
Jim Foster: Yeah, the automated system will come sort of in the back half of the year. I think a realistic way to look at that would be second half.
Jim Foster: The automated PCS is [moves] us into the quality control labs of the manufacturers sites have smaller devices sort of remotely utilized and then at some point it’s a much larger number of samples that could go to the PC lab and so that’s really powerful and helpful to be able to load this thing up and walk away and have this thing actually to read cartridges on an automated basis, and the initial interest is quite high on a pre-launch basis. We sized that on our last call, we indicated that that’s about a $300 million market opportunity, sort of QC lab focus of which we only have about 10% share. So we've a big opportunity there and while there are certainly competing products we don’t see anything out there with this sort of capability and from an automatic point of view. In terms of helping you size this we’re certainly kind of stay away from breaking out the margin contribution. In terms of the revenue contribution I think we indicated that it’s part of – its part of other which includes …
Jim Foster: Avian and this is the larger, fastest growing portion of the business that we sort of watched the growth in those two, you can size that relatively [easily].
Jim Foster: It’s really added to it. And you see clients sort of adopting the technology throughout their organization and getting comfortable with it remotely and then really wanting to use it in a more robust way. So the potential for greater penetration on a per client basis is much higher.
Jim Foster: In general, we are looking at cartridge sales while we are very happy with the margin on the devices. This is a razor blade business and the MCS device we use a lot more cartridges sort of by definition and that’s pretty powerful value proposition for us.
Jim Foster: I think it’s quite important to the client in the big deal that we’ve signed where we are using many of our facilities in multiple parts of the world. We are able to use the power of the specialization of those facilities and we are able to coordinate it in a way where the client is working quite centrally and in some areas therapeutic, therapeutic area expertise is working with therapeutic area expertise that we have. But in all events they’re looking for us to help them pull it together because that’s way we drive value of the realignment of our infrastructure that we made whenever, it was six months ago or so, where we’ve got the formally separate RMS and PCS operating business managed by single process in North America and single process in Asia and Europe have been quite helpful in delivering these services in a more integrated way. And previously, obviously the work that we have done at our preclinical business by having a metric system that pull the disparate parts and pieces together has also been helpful. So, yes, the value across the portfolio is increasingly important to our clients. Our ability to manage that is critical, but rather than viewing us in a fragmented fashion we are able to have a lot more robust relationship because of the expertise we have across the world.
Jim Foster: I’d say that for clients of scale, the ability to buy across the continuum has become increasingly important. We are seeing structurally clients at the large pharma is being responsible for late discovery or early development, I don’t know what they call it, at their individual companies, really focused on extend pretty much across all of that we do. And it’s quite important to them. So I think that the scale and the breadth of the portfolio continues to be a distinguishing and competitive feature for us.
Jim Foster: I don’t know if it’s better model. We’ve been talking a lot to our clients about insourcing, outsourcing strategy where they can do both. So they can utilize our facilities on an external basis when they don’t have the capacity or the specific ability to do, let’s say some sort of specialty tox. And then in facilities that they want to keep or need to keep for whatever reason, expertise, lets say, the ability to have someone else to manage that and hopefully manage it more efficiently I think is – really gets their attention. Then the ability to move compounds within that system either doing it internally at their own facilities with their people that we could manage or at our facility, with our people that we obviously manage gives them much bigger footprint and enhances the flexibility. So I think the clients are increasingly interested in trying that structure. We have several conversations going on right now about that.
Tom Ackerman: It actually was an operating income, it was in SG&A because it was not an income tax it would be above the line. So that was in SG&A, Eric.
Tom Ackerman: What we had said in the aggregate was; we do have a number of cost benefits playing through 2012 principally as a result of the Q4 actions. But in addition, unfortunately going the other way, we do have merit increases as well as other inflationary pressures, so once we continue to cut cost, things like merit increases, and price increases from our vendors even though in some cases those are lower, continues to almost offset the cost savings that we’re having.
Tom Ackerman: Well, our comments about expecting improvement are really based on the full-year numbers. So, while we did have a good Q4, our numbers for the full-year are slightly below that, and of course the – as we mentioned in the remarks, the tax – non-income based tax pickup in the fourth quarter is not really something that we’d expect to recur clearly.Robert Jones – Goldman Sachs Group, Inc: Okay, so the …
Tom Ackerman: Well, it’s -- the merit-based increases are more of a inflationary equity type adjustment. I believe in December we talked about the range of increases, which – while not uniform across the company, it’s fairly consistent based on the localized market. So, we’ve struggled through the last few years with reductions in headcount, one year, where we had no merit increases and another year where it was low inflation. So -- this year, merit is little bit more across the board, obviously, any individuals who are not performing up to appropriate desiring in those particular areas aren’t getting awarded as much, but it’s any exceptions like that or more geographic or an individualized basis rather than on a business basis.
Tom Ackerman: We anticipated having some issues to deal with. The amount was a little bit lucid. So, I’d say that was something that we were looking at, but took a fair amount of analysis on our part actually come up with the number.
Tom Ackerman: Yes, what we had said was on a constant currency as you noted, our guidance for ’12 was 1% to 3%. We did say that we expect that the RMS to outperform that and we did say that we expect that the preclinical to be a little bit less than that which obviously balances out the numbers. On both segments, as we just talked about somewhat extensively 53rd week was obviously was a benefit in Q4 and 2011 it obviously creates a slight win going into 2011 – 2012 of about the same percentage on a full-year basis, which we said was about 1% for the full-year. Pricing in RMS is overall for 2012 is somewhere in the 2-ish percentage range. So clearly that’s part of the uptick in RMS. Next year we talk about some business is being a little bit better like Discovery and Vitro and some of the small models continuing to be challenged as well as the large model business on the PCS side, we talked about regulated talks, continuing to be a little bit of a drag and in the non-GLP areas that would continue to be developed positively. So basically in a nutshell that’s how I’d attempt to answer your question.
Tom Ackerman: Yeah more or less, I mean, with the growth rate overall, we don’t expect a lot of dynamic activity quarter-to-quarter. If you think about where we are year-over-year, we did say specifically given the uptick in Q4 because of the 53rd week that we think PCS will be down sequentially going into Q1 and really from there it will probably move sideways to up notionally quarter-over-quarter, but nothing dramatic.
Tom Ackerman: I’d say yes, with the exception of it will depend on how meaningful those partnerships were. So if we were to announce another meaningful partnership, it would be clearly difficult to do that without affecting headcount directionally in any manner. So, our view would be continue to try to increase business, win strategic partnership awards, and in some cases we might have to add incremental heads, but not as many as we would have added historically by being more efficient.Todd Van Fleet – First Analysis: Okay. Thank you.
Tom Ackerman: Well, I’d say given the few projects that are ongoing now and part of the reason for the little bubble in Q4, we will probably see it, not as quite heavy as Q4, but my guess would be that in 2012 we will see a little bit more activity from a timing standpoint in the first half of the year than the second half of the year. But even though we had a little bubble in Q4, as we said, we don’t expect to spend any more capital in 2012 and nor do we expect to spend at that kind of a run rate in a given quarter.James Kumpel – BB&T Capital Markets: Okay. Thank you very much.
James Foster: Yeah. We never how much space the clients have, unfortunately. So, it’s hard to size. We know that they’ve more space than the CROs collectively because still the majority of work is done there. The CROs – we took our 20% of our space over the last two years and most of our major competitors have done the same, a couple have talked about doing even some more in 2012 as demand isn’t there. Certainly, we’ve seen some of the big clients spaced out, and there have been some recent announcements by other clients to do the same. So, the good news is that capacity is contracting in the industry, our capacity utilization has improved. I suspect others have as well. There is still a lot of space available. The bad news is that puts a little pressure on the margins and price in the short-term, but the good news is that work comes outside of clients, we won’t have the need to build any incremental space. So, I think that’s quite a positive. Our information on China would be a little bit dated, but I can just tell you that when we were there with our facility, there wasn’t a significant level of consistent interest, it was very fragmented and we didn’t have any large clients to do a significant amount of work. I’d imagine that hasn’t changed much. But having said that, you only have, I don’t know, 500,000 or 600,000 square feet as supposed to several million, I think it was 8 million in the state. So we’ve a much smaller square footage profile. I’d suspect it’s still thoroughly underutilized and that everyone is in a loss, continues to be in loss position over there. Probably on a proportional basis, the capacity in the state is probably very utilized, but still a lot left to go. So, it’s hard to say that’s probably in the U.S. probably a couple of years, two to three years of space left before there is a need for people to open additional space.
James Foster: Sure. We’ve a very strong senior team. Most of the people have been here relatively long period of time. So, we’ve really good stability and amazing longevity statistics, people that know the industry well, the clients well, and we all work well together, that’s -- the office group is about 30 people. Most of the businesses that we’ve either built from the ground up or acquired have similar strong longevity statistics as well, and we’ve very low turnover over the last few years. So, I’d say that we’re retaining our people very well. I think we take competitively. I think people work here because what we do makes a difference. And I’d call it a stable environment, obviously not withstanding the workflows reductions we’ve had primarily in our preclinical business over the last three years where mostly we take junior people out, like, a few at sort of mid-management level.
James Foster: It has been completed. And we had it now for about six months and we’ve it completed during the budget process, which was extremely helpful, and just to add, our international sales meeting, which we’ve in mid-January and it just was very powerful the interface between the operating folks and the sales organization. So yeah, we completed it, we’re extremely pleased with it, the client feedback is great, and the sales force seems better congealed than ever.
James Foster: I mean it could, our academic sales have increased significantly over the last few years, we bid on lots of large government contracts, many of which are funded by the NIH, we’re winning a lot of them. So obviously they could be incremental work coming out. We also sell our products directly into the NIH and sales there we’ve been focusing on it more, more thoroughly and sales there have increased as well. So obviously upside in spending certainly could be beneficial as I said earlier as the price point versus the competition for our research models in particular has flattened, we’re getting a lot more traction from a share point of view.
James Foster: Price increase has been received well, with virtually very little pushback and we’re pleased by that.
